A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is single, centre trial to study the safety and efficacy of Bone marrow derived autologous MNCS(100 million per dose)trial to be conducted for 36 months in stroke patients , the primary outcome measure will be the improvement in muscle power of Body and face

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Stem Cell Therapy in Stroke

NCT02245698

Stroke

WITHDRAWN PHASE1

Efficacy Study of CD34 Stem Cell in Chronic Stroke Patients

NCT00950521

Stroke Middle Cerebral Artery Infarction

COMPLETED PHASE2

Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke

NCT03296618

Ischemic Motor Stroke, Chronic

UNKNOWN PHASE1

Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke

NCT02564328

Stroke

UNKNOWN PHASE1

Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke

NCT01714167

Stroke

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is single centre trial to study the safety and efficacy of Bone marrow derived autologous MNCS(100 million per dose)trial to be conducted for 36 months in stroke patients , the primary outcome measure will be the improvement in muscle power of Body and face

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke,

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transfer of autologous MNC intrathecally

Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.

Group Type OTHER

Intra thecal transplantation of Autologous Stem Cells

Intervention Type OTHER

Intra thecal transplantation of Autologous Stem Cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intra thecal transplantation of Autologous Stem Cells

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient should suffer from stroke due to cerebral infarct or Haemorrhage or accelerated hypertension.
* willingness to undergo bone marrow derived autologous cell therapy.
* patient those provide fully Informed consent form for the study.
* Ability and willingness to regular visit to hospital and follow up during the protocol Procedure.

Exclusion Criteria

* Patients with pre - existing or Current systemic disease such as lung , liver ( exception; History of uncomplicated Hepatitis A),gastrointestinal, Cardiac , Immunodeficiency,(including HIV) Or laboratory Investigation that could cause a neurological defect.History of Life threating Allergic or immune- mediated reaction.
* Alcohol and drug abuse / dependence.
* Severe skin infection.
* Haemodynamically unstable.
* subject with primary and secondary diabetes , Insulin depenence,

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes